Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
ALKEM LABORATORIES TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALKEM LABORATORIES Mar-23 |
TEVA PHARMA Dec-13 |
ALKEM LABORATORIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,625 | 3,480 | - | |
Low | Rs | 2,835 | 3,023 | - | |
Sales per share (Unadj.) | Rs | 970.1 | 1,997.4 | - | |
Earnings per share (Unadj.) | Rs | 84.2 | 124.8 | - | |
Cash flow per share (Unadj.) | Rs | 110.2 | 286.2 | - | |
Dividends per share (Unadj.) | Rs | 50.00 | 109.23 | - | |
Avg Dividend yield | % | 1.5 | 3.4 | 46.1% | |
Book value per share (Unadj.) | Rs | 756.4 | 2,218.7 | - | |
Shares outstanding (eoy) | m | 119.57 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.3 | 1.6 | 204.5% | |
Avg P/E ratio | x | 38.4 | 26.1 | 147.2% | |
P/CF ratio (eoy) | x | 29.3 | 11.4 | 258.1% | |
Price / Book Value ratio | x | 4.3 | 1.5 | 291.3% | |
Dividend payout | % | 59.4 | 87.5 | 67.8% | |
Avg Mkt Cap | Rs m | 386,207 | 2,757,543 | 14.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 21,314 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,685.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,354.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 115,993 | 1,693,781 | 6.8% | |
Other income | Rs m | 2,161 | 0 | - | |
Total revenues | Rs m | 118,153 | 1,693,781 | 7.0% | |
Gross profit | Rs m | 15,065 | 463,843 | 3.2% | |
Depreciation | Rs m | 3,104 | 136,910 | 2.3% | |
Interest | Rs m | 1,074 | 33,269 | 3.2% | |
Profit before tax | Rs m | 13,048 | 293,664 | 4.4% | |
Minority Interest | Rs m | 0 | 1,334 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,775 | -0.0% | |
Tax | Rs m | 2,980 | -3,585 | -83.1% | |
Profit after tax | Rs m | 10,068 | 105,809 | 9.5% | |
Gross profit margin | % | 13.0 | 27.4 | 47.4% | |
Effective tax rate | % | 22.8 | -1.2 | -1,870.4% | |
Net profit margin | % | 8.7 | 6.2 | 138.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 86,064 | 1,143,974 | 7.5% | |
Current liabilities | Rs m | 37,071 | 997,642 | 3.7% | |
Net working cap to sales | % | 42.2 | 8.6 | 488.9% | |
Current ratio | x | 2.3 | 1.1 | 202.5% | |
Inventory Days | Days | 33 | 91 | 35.9% | |
Debtors Days | Days | 67 | 96 | 70.0% | |
Net fixed assets | Rs m | 37,245 | 553,226 | 6.7% | |
Share capital | Rs m | 239 | 4,169 | 5.7% | |
Net worth | Rs m | 90,447 | 1,881,470 | 4.8% | |
Long term debt | Rs m | 0 | 866,068 | 0.0% | |
Total assets | Rs m | 124,541 | 3,870,833 | 3.2% | |
Interest coverage | x | 13.2 | 9.8 | 133.8% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.4 | 212.8% | |
Return on assets | % | 8.9 | 3.6 | 249.0% | |
Return on equity | % | 11.1 | 5.6 | 197.9% | |
Return on capital | % | 15.6 | 4.9 | 316.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,825 | 269,901 | 6.2% | |
From Investments | Rs m | 1,128 | -95,637 | -1.2% | |
From Financial Activity | Rs m | -17,608 | -323,765 | 5.4% | |
Net Cashflow | Rs m | 416 | -149,500 | -0.3% |
Compare ALKEM LABORATORIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare ALKEM LABORATORIES With: ZENITH HEALTH SANDU PHARMA ORCHID PHARMA TRIDENT LIFELINE AURO LAB.
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.